PeppiLibrary

Sexual Health

PT-141 peptide reference

FDA-approved melanocortin agonist for premenopausal HSDD. Acute libido enhancer.

Last reviewed May 6, 2026 FDA-approved FDA approved
Peppi reviewing PT-141 notes
Default dose label1.75 mg
Preferred routeSubQ
Frequency labelAs-needed; max 1× per 24 hours, 8× per month per label
Storage window28 days mixed

Evidence snapshot

FDA-approved

Evidence maturityFDA approved
FDA-approved (Vyleesi, 2019); Phase 3 trials for HSDD

Prescription medication

Route map

How records are usually labeled

1 SubQ

Rotate sites if dosing repeatedly within a week.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C (commercial); compounded vials refrigerated.
After mixRefrigerate 2–8 °C, use within 28 days.
Use-by cue28 days after mixing
Mixed vial window28 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 10 mg vial
Dose 1.75 mg
Route SubQ
Review 28d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for PT-141. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

PT-141 (bremelanotide) is a synthetic cyclic 7-amino-acid peptide and melanocortin receptor agonist (MC1R/MC3R/MC4R). It was FDA-approved in 2019 (as Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women, with off-label and research use in men. Effects are CNS-mediated rather than vascular — distinct from PDE5 inhibitors.

Also known as: Bremelanotide, Vyleesi.

Premenopausal HSDD (FDA indication)Off-label libido supportED research adjunct

Mechanism and timing snapshot

Non-selective melanocortin receptor agonist (MC1R/MC3R/MC4R). Acts centrally in the hypothalamus to modulate sexual desire pathways via dopaminergic signalling.

Onset label30 min
Catalog onset field, when available.
Half-life label2.7 hr
~2–3 hours; effects last 6–12 hours
Duration label8 hr
Catalog duration field, when available.
subQ ~100%
intranasal Moderate (failed development path)
oral Negligible

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose1.75 mg
Catalog dose range1 mg - 1.75 mg
Default routeSubQ
Frequency labelAs-needed; max 1× per 24 hours, 8× per month per label
Best time label45–60 min before anticipated sexual activity.
Food noteNone significant.

Catalog protocol note

1.75 mg subQ at least 45 min before anticipated activity; do not exceed 1× per 24 hours.

Routes and site notes

Available route labelsSubQ
Preferred route labelSubQ
Common site labelsAbdomen, Thigh
Site rotation noteRotate sites if dosing repeatedly within a week.

Chemistry

SequenceAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Amino acids7
Molecular formulaC50H68N14O10
Molecular weight1025.18 Da

Vial, reconstitution, and storage

Supply formPre-filled auto-injector (commercial); lyophilized powder (compounded)
Typical vial size10 mg
DiluentBacteriostatic water (compounded only)
Diluent volume5 mL
Concentration noteCompounded 10 mg in 5 mL → 0.875 mL = 1.75 mg label dose. Auto-injector pre-dosed.
Before reconstitutionRefrigerate 2–8 °C (commercial); compounded vials refrigerated.
After reconstitutionRefrigerate 2–8 °C, use within 28 days.
Reconstituted shelf life28 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Nausea (~40%, often severe)
  • Facial flushing
  • Headache
  • Injection-site reactions
  • Transient blood pressure increase
  • Darkening of moles or skin (long-term)

Contraindications and warnings

  • Uncontrolled hypertension
  • Cardiovascular disease
  • Pregnancy
  • Transient BP elevation observed in trials — caution with cardiovascular history.

Other considerations

  • Nausea is common and often severe — start at lower dose if compounded.
  • Effects are CNS — desire-focused, not erection-focused like sildenafil.
  • Per label, do not exceed 8 doses per month.

Evidence and regulatory context

Evidence levelFDA-approved (Vyleesi, 2019); Phase 3 trials for HSDD
FDA approvedYes
Regulatory statusPrescription medication
Prescription requiredYes
Approved countriesUS

Stacking and cycle notes

Stacks well withNot listed
Avoid combining notePDE5 inhibitors at high doses (additive hypotension theoretical)
Typical cycle labelAs-needed
Typical break labelBuilt-in by 24h spacing rule
Cycle guidanceDesigned for as-needed use; not a daily peptide. Monthly cap is per FDA label.

Tracking tips

  • Take 45–60 min before activity — onset is not instant.
  • If nausea is severe, talk to a clinician about a lower compounded dose.
  • Acts on desire, not on erection — different mechanism than sildenafil/tadalafil.

References

Track it in Peppi

Keep PT-141 records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for PT-141?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use PT-141?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export PT-141 records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026